News articles about DBV Technologies (NASDAQ:DBVT) have been trending somewhat positive on Monday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. DBV Technologies earned a news impact score of 0.05 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.9817064819336 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
DBVT has been the subject of a number of analyst reports. BidaskClub upgraded DBV Technologies from a “strong sell” rating to a “sell” rating in a research report on Thursday, December 21st. Zacks Investment Research downgraded DBV Technologies from a “hold” rating to a “sell” rating in a research report on Monday, December 25th. Citigroup set a $57.00 price target on DBV Technologies and gave the stock a “buy” rating in a research report on Wednesday, February 14th. HC Wainwright restated a “buy” rating on shares of DBV Technologies in a research report on Thursday, March 15th. Finally, Deutsche Bank set a $33.00 price target on DBV Technologies and gave the stock a “buy” rating in a research report on Tuesday, March 27th. Two analysts have rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the stock. DBV Technologies currently has an average rating of “Hold” and a consensus price target of $46.00.
Shares of DBVT opened at $23.44 on Monday. The firm has a market capitalization of $1,336.92, a P/E ratio of -9.05 and a beta of 0.97. DBV Technologies has a 52-week low of $20.08 and a 52-week high of $50.57. The company has a quick ratio of 4.37, a current ratio of 4.37 and a debt-to-equity ratio of 0.01.
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which is in Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.